Sharon L. Barrans
Haematology Malignancy Diagnostic Service (HMDS)
St James's Institute of Oncology
Leeds
United Kingdom
Name/email consistency: high
- Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. Barrans, S., Crouch, S., Smith, A., Turner, K., Owen, R., Patmore, R., Roman, E., Jack, A. J. Clin. Oncol. (2010)
- Strong expression of FOXP1 identifies a distinct subset of diffuse large B-cell lymphoma (DLBCL) patients with poor outcome. Barrans, S.L., Fenton, J.A., Banham, A., Owen, R.G., Jack, A.S. Blood (2004)
- The t(14;18) is associated with germinal center-derived diffuse large B-cell lymphoma and is a strong predictor of outcome. Barrans, S.L., Evans, P.A., O'Connor, S.J., Kendall, S.J., Owen, R.G., Haynes, A.P., Morgan, G.J., Jack, A.S. Clin. Cancer Res. (2003)
- The detection of t(14;18) in archival lymph nodes: development of a fluorescence in situ hybridization (FISH)-based method and evaluation by comparison with polymerase chain reaction. Barrans, S.L., Evans, P.A., O'Connor, S.J., Owen, R.G., Morgan, G.J., Jack, A.S. J. Mol. Diagn (2003)
- Rearrangement of the BCL6 locus at 3q27 is an independent poor prognostic factor in nodal diffuse large B-cell lymphoma. Barrans, S.L., O'Connor, S.J., Evans, P.A., Davies, F.E., Owen, R.G., Haynes, A.P., Morgan, G.J., Jack, A.S. Br. J. Haematol. (2002)